Breaking News

Baxter Completes Gambro Acquisition

September 6, 2013

Enhances global renal portfolio of product and therapies

Baxter International, Inc. has completed the acquisition of Gambro AB, a global medical technology company based in Lund, Sweden, for approximately $3.9 billion, expanding its global renal business and gaining a comprehensive portfolio of product and therapies.
The acquisition provides a broad dialysis product portfolio and global footprint that will allow Baxter to grow product sales in Europe, where Gambro has an extensive presence, as well as Latin America and Asia-Pacific.
Brik Eyre has been named president of the combined Renal business and has been elected a corporate officer of Baxter. He reports to Robert M. Davis, president of Baxter’s Medical Products business. Mr. Eyre joined the company in 2008 and previously served as the general manager of U.S. Medication Delivery. Prior to this he served as general manager for Baxter’s BioPharma Solutions business.
“The combination of these two respected renal leaders will enable Baxter to better serve healthcare providers and patients through a collective offering of innovative renal products and therapies,” said Robert L. Parkinson, Jr., chairman and chief executive officer of Baxter. “Together, we will advance the state of dialysis care for patients with kidney disease worldwide.”
blog comments powered by Disqus
  • Packaging Equipment Close-Up

    Packaging Equipment Close-Up

    Kristin Brooks, Contract Pharma||March 9, 2016
    To meet the wide-ranging needs of the marketplace, suppliers and contract packagers are looking to deliver flexible solutions.

  • Single-use Technology Integral to Advancing Biomanufacturing

    Single-use Technology Integral to Advancing Biomanufacturing

    Nigel Walker, Thatu2019s Nice LLC / Nice Insight||March 9, 2016
    Innovative process technologies are a necessity for today’s biopharmaceutical contract manufacturers

  • Parenteral Outsourcing Trends

    Parenteral Outsourcing Trends

    Tim Wright, Editor||March 9, 2016
    Contract Pharma asked a roundtable of business leaders from Symbiosis, Grifols, Althea, LSNE and Baxter to discuss key trends in the parenteral dosage development and manufacturing market